Sign In
Buy FENC
$9.14
-0.84 (-8.42%)
At Close: Jun 03, 2026
Fennec Pharmaceuticals Announces Management Change
06:00am, Monday, 01'st Jul 2024
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian H
Fennec Announces Results of Annual Meeting
04:35pm, Tuesday, 25'th Jun 2024
RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy
Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript
01:15pm, Tuesday, 14'th May 2024
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Rosty Raykov - Chief Executive Officer and Director Robert Andrade - Chief Fina
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
08:16am, Tuesday, 14'th May 2024
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $0.23 per share a year ago.
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
06:03am, Tuesday, 14'th May 2024
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
06:15pm, Tuesday, 07'th May 2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa
Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
11:06am, Thursday, 02'nd May 2024
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
08:16am, Thursday, 21'st Mar 2024
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.26 per share a year ago.
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
06:00am, Thursday, 21'st Mar 2024
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~
Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up
11:16am, Tuesday, 19'th Mar 2024
Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.
Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Tuesday, 19'th Mar 2024
Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
06:01am, Tuesday, 19'th Mar 2024
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com
Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-i
Wall Street Analysts See a 64.61% Upside in Adherex Technologies Inc. (FENC): Can the Stock Really Move This High?
10:56am, Wednesday, 13'th Mar 2024
The consensus price target hints at a 64.6% upside potential for Adherex Technologies Inc. (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price
08:39pm, Wednesday, 06'th Mar 2024
Fennec released sales guidance for Q4 2023, exceeded analyst expectations. A pending EU launch of PEDMARK® provides a near term opportunity for the Company to finalize an EU partnership. Revenue grow
